GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » Total Current Liabilities

Propanc Biopharma (Propanc Biopharma) Total Current Liabilities : $3.69 Mil (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Propanc Biopharma's total current liabilities for the quarter that ended in Mar. 2024 was $3.69

Propanc Biopharma Total Current Liabilities Historical Data

The historical data trend for Propanc Biopharma's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma Total Current Liabilities Chart

Propanc Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.40 3.74 3.08 3.06 3.16

Propanc Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.06 3.16 3.13 3.76 3.69

Propanc Biopharma Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Propanc Biopharma's Total Current Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.621+0.527
+Other Current Liabilities+Current Deferred Liabilities
=1.01+0
=3.16

Propanc Biopharma's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.066+0.883
+Other Current Liabilities+Current Deferred Liabilities
=0.739+0
=3.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Propanc Biopharma Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Propanc Biopharma (Propanc Biopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » Total Current Liabilities
Comparable Companies
CALA QBIO RGMP RSPI HGEN RGIN MYMX RGTPQ RBSH ATRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Website
https://www.propanc.com
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Executives
Josef Zelinger director 59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano officer: CFO & Secretary C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon director BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz director, officer: CEO, CFO, Secretary, Treasurer 1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146